Popek-Marciniec Sylwia, Styk Wojciech, Wojcierowska-Litwin Magdalena, Szudy-Szczyrek Aneta, Dudek Paul, Swiderska-Kolacz Grazyna, Czerwik-Marcinkowska Joanna, Zmorzynski Szymon
Department of Cancer Genetics with Cytogenetic Laboratory, Medical University of Lublin, 20-059 Lublin, Poland.
Department of Psychology, Medical University of Lublin, 20-059 Lublin, Poland.
J Clin Med. 2023 Mar 20;12(6):2384. doi: 10.3390/jcm12062384.
(1) Background: Chemokines and chemokine receptors play an important role in tumor development. The aim of this study was to check the significance of and variants with response rate, survival, and the level of regulated on activation, normal T cells expressed and secreted (RANTES/CCL5) in multiple myeloma (MM) patients; (2) Methods: Genomic DNA from 101 newly diagnosed MM patients and 100 healthy blood donors were analyzed by Real-time PCR method (for and genotyping). In a subgroup of 70 MM patients, serum samples were collected to determine the level of RANTES; (3) Results: multivariate Cox regression showed increased risk of disease relapse or progression (HR = 4.77; = 0.01) in MM patients with CG + CC genotypes of rs2280788. In contrast, CT + TT genotypes of rs2107538 were associated withdecreased risk of death (HR = 0.18; = 0.028) and disease relapse or progression (HR = 0.26; = 0.01). In MM patients with major genotypes of rs2280789, rs2280788, and rs2107538, higher survival rates were observed in response to treatment with thalidomide and bortezomib. Statistically significant lower RANTES levels were seen in minor genotypes and heterozygotes of and variants; (4) Conclusions: Major genotypes of variants may be independent positive prognostic factors in MM.
(1) 背景：趋化因子和趋化因子受体在肿瘤发展中起重要作用。本研究的目的是检测多发性骨髓瘤（MM）患者中[具体基因]变体与缓解率、生存率以及活化调节正常T细胞表达和分泌因子（RANTES/CCL5）水平的相关性；(2) 方法：采用实时PCR法（用于[具体基因]基因分型）分析101例新诊断MM患者和100例健康献血者的基因组DNA。在70例MM患者的亚组中，收集血清样本以测定RANTES水平；(3) 结果：多因素Cox回归显示，rs2280788基因CG + CC基因型的MM患者疾病复发或进展风险增加（HR = 4.77；P = 0.01）。相比之下，rs2107538基因CT + TT基因型与死亡风险降低（HR = 0.18；P = 0.028）和疾病复发或进展风险降低（HR = 0.26；P = 0.01）相关。在rs2280789、rs2280788和rs2107538主要基因型的MM患者中，观察到沙利度胺和硼替佐米治疗后的生存率较高。在[具体基因]变体的次要基因型和杂合子中，RANTES水平在统计学上显著较低；(4) 结论：[具体基因]变体的主要基因型可能是MM独立的阳性预后因素。
